ArticleOncoimmunology
Characterization of the cryoablation-induced immune response in kidney cancer patients.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04429321 (UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.Nature communications · 2024Trial
- Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.Nature communications · 2021Trial
- Article
- Spontaneous Regression of Clear Cell Renal Cell Carcinoma Metastases or Immune Restoration?Current oncology (Toronto, Ont.) · 2026Article
- Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors.Frontiers in oncology · 2026Review
- Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers.Frontiers in oncology · 2026Review
- Progress of Immune-Inducible Biomaterials for Post-Ablation Cancers.Advanced healthcare materials · 2025Review
- Interventional oncology and immunotherapy: current status and future perspectives.Frontiers in immunology · 2025Review
- Influence of cryoablation versus operation on circulating lymphocyte subsets in patients with early-stage renal cell carcinoma.BMC cancer · 2024Article
- Modern cancer therapy: cryoablation meets immune checkpoint blockade.Frontiers in oncology · 2024Review
- T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma.Current issues in molecular biology · 2023Article
- Immunomodulatory effect of locoregional therapy in the tumor microenvironment.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Anti-PD-L1 antibody enhances curative effect of cryoablationActa pharmaceutica Sinica. B · 2023Article
- Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease.Frontiers in oncology · 2023Article
- Progress in the cryoablation and cryoimmunotherapy for tumor.Frontiers in immunology · 2023Review
- Gaseous nitric oxide tumor ablation induces an anti-tumor abscopal effect.Cancer cell international · 2022Article
- Comparative analysis of the immune response to RFA and cryoablation in a colon cancer mouse model.Scientific reports · 2022Article
- Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy.Frontiers in immunology · 2022Review
- Article
- Selective Arterial Embolization with N-Butyl Cyanoacrylate Prior to CT-Guided Percutaneous Cryoablation of Kidney Malignancies: A Single-Center Experience.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryoablation is one of treatment modalities for kidney cancer and is expected to induce strong local immune responses as well as systemic T-cell-mediated immune reactions that may lead to the regression of distant metastatic lesions. Thus, the characterization of T cell repertoire and immune environment in tumors before and after treatment should contribute to the better understanding of the cryoablation-induced anticancer immune responses. In this study, we collected tumor tissues from 22 kidney cancer patients, before cryoablation and at 3 mo after cryoablation. In addition, blood samples were collected from 14 patients at the same time points. We applied a next generation sequencing approach to characterize T cell receptor β (TCRB) repertoires using RNAs isolated from tumor tissues and peripheral blood mononuclear cells. TCRB repertoire analysis revealed the expansion of certain T cell clones in tumor tissues by cryoablation. We also found that proportions of abundant TCRB clonotypes (defined as clonotypes with ≥ 1% frequency among total TCRB reads) were significantly increased in the post-cryoablation tissue samples than those of pre-cryoablation tumor samples. Some of these TCRB clonotypes were found to be increased in peripheral blood. Expression analysis of immune-related genes in the tissues of pre- and post-cryoablation showed significantly elevated transcriptional levels of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.